Extracellular nucleotides and adenosine regulate endocrine pancreatic functions such as insulin secretion by Langerhans islet ␤-cells via the activation of specific P2 and P1 receptors. Membrane-bound ectonucleotidases regulate the local concentration of these ligands and consequently control the activation of their receptors. The objective of this study was to identify and localize the major ectonucleotidases, namely NTPDases and ecto-5=-nucleotidase, present in the endocrine pancreas. In addition, the potential implication of ecto-ATPase activity on insulin secretion was investigated in the rat ␤-cell line INS-1 (832/13). The localization of ectonucleotidase activity and protein was carried out in situ by enzyme histochemistry and immunolocalization in mouse, rat, and human pancreas sections. NTPDase1 was localized in all blood vessels and acini, and NTPDase2 was localized in capillaries of Langerhans islets and in peripheral conjunctive tissue, whereas NTPDase3 was detected in all Langerhans islet cell types. Interestingly, among the mammalian species tested, ecto-5=-nucleotidase was present only in rat Langerhans islet cells, where it was coexpressed with NTPDase3. Notably, the inhibition of NTPDase3 activity by BG0136 and NF279 facilitated insulin release from INS-1 (832/13) cells under conditions of low glycemia, probably by affecting P2 receptor activation. NTPDase3 activity also regulated the inhibitory effect of exogenous ATP in the presence of a high glucose concentration most likely by controlling adenosine production. In conclusion, all pancreatic endocrine cells express NTPDase3 that was shown to modulate insulin secretion in rat INS-1 (832/13) ␤-cells. Ecto-5=-nucleotidase is expressed in rat Langerhans islet cells but absent in human and mouse endocrine cells.
INSULIN IS SYNTHESIZED AND SECRETED in a highly regulated manner by ␤-cells, the dominant cell population in Langerhans islets. Physiological glycemia elevations raise the rate of metabolism in ␤-cells, thereby leading to an increase in intracellular ATP/ADP ratio and the closure of ATP-sensitive K ϩ channels (43) . The ensuing cell membrane depolarization triggers the opening of the voltage-dependent Ca 2ϩ channels and the increase of intracellular Ca 2ϩ concentration, leading to the exocytosis of insulin-containing granules (43) . Upon glucose stimulation, insulin secretion from ␤-cells is accompanied by the release of ATP (11, 25, 28, 49) at maximal concentrations reaching up to 25 M at the cell surface (20) . Extracellular ATP and ADP and synthetic P2 receptor agonists such as 2-methylthioadenosine 5=-triphosphate and adenosine 5=-(␤-thio)diphosphate increase glucose-induced insulin secretion in a variety of species, including rat and human (9, 17, 26, 39) . The situation is not as clear in the mouse, since extracellular nucleotides were reported to either diminish (34, 44, 46) or increase insulin secretion (2, 45) , suggesting that the system might be rather complex. Further investigation should be performed to clarify the situation.
Extracellular nucleotides exert their physiological effects via the activation of P2 receptors, including ionotropic P2X and metabotropic P2Y receptors (7) . The activation of both P2X and P2Y receptors in ␤-cells increases intracellular Ca 2ϩ levels via two different pathways; P2X activation promotes Ca 2ϩ influx, whereas P2Y activation leads to Ca 2ϩ mobilization from intracellular stores (38) . However, the identity and the respective contribution of the P2 receptor(s) involved in the regulation of insulin secretion have yet to be determined. Several studies point to the ADP receptor P2Y 1 as a key player in this process (34, 51) . However, the involvement of other P2 receptors, such as P2Y 6 (2, 44, 45) , P2Y 13 (1), P2X 3 (26) , and an undetermined P2X receptor (47, 49) , has also been suggested. Thus the extracellular nucleotide-mediated regulation of insulin secretion appears to be complex and may involve a number of nucleotide receptors.
The concentration of extracellular nucleotides, and thus P2 receptor activation, is regulated by different families of ectonucleotidases that are integral plasma membrane enzymes, with their active site facing the extracellular milieu (60) . Most notably, the ectonucleoside triphosphate diphosphohydrolase (NTPDase) family plays a major role in tri-and diphosphonucleoside hydrolysis. Four plasma membrane-bound NTPDases have been cloned, namely NTPDase1, -2, -3, and -8 (50) . These enzymes have distinct localizations and biochemical properties. NTPDase1 hydrolyzes ATP and ADP equally well, NTPDase2 preferentially hydrolyzes triphosphonucleosides, and NTPDase3 and -8 have intermediate hydrolysis profiles (31) . The hydrolysis of ATP and ADP by NTPDases yields AMP as a final product that can be fully dephosphorylated to adenosine by ecto-5=-nucleotidase (10) . Extracellular adenosine is a biologically effective molecule that activates metabotropic P1 receptors, namely A 1 , A 2A , A 2B , and A 3 (7) . Notably, adenosine via the A 1 receptor diminishes glucose-induced insulin secretion by murine Langerhans islets (5, 8, 23, 27) .
Although the effects of extracellular nucleotides and nucleosides on insulin secretion have been documented, the function of ectonucleotidase(s) in this process remains basically unknown. In this work, we identified the ectonucleotidases expressed in the Langerhans islets of mouse, rat, and human and determined the involvement of ecto-ATPase activity on insulin secretion.
MATERIALS AND METHODS

Materials
RPMI 1640 cell culture medium was obtained from Wisent (StBruno, QC, Canada). Adenosine 5=-(␣,␤-methylene)diphosphate (␣,␤-meADP), (NH 4)2S, 1-naphthol-3,6-disulfonic acid disodium salt (BG0136), ␤-mercaptoethanol (cell culture tested), levamisole, nucleotides, paraformaldehyde, and purified isotype control immunoglobulins were provided by Sigma-Aldrich (Oakville, ON, Canada). Aqueous hematoxylin was purchased from Accurate Chemical & Scientific (Westbury, NY), 4=,6-diamidino-2-phenylindole (DAPI) was from Molecular Probes (Invitrogen, Burlington, ON, Canada), dextran T-250 (MW ϭ 200,000 -300,000) was from MP Biomedicals (Solon, OH), Mowiol 4 -88 was from Calbiochem (VWR Canlab, Mississauga, ON, Canada), and NF279 was from Tocris Bioscience (Ellisville, MO).
Antibodies
All primary antibodies used in this study have previously been validated: rabbit C9F (14, 21) and guinea pig mN1-2 C (40) to mouse NTPDase1, rabbit mN2-36 L to mouse NTPDase2 (3), rabbit BZ3-4F to rat NTPDase2 (21, 53) , guinea pig mN3-3C to mouse NTPDase3 (40) , rabbit rN3-1L to rat NTPDase3 (57), mouse monoclonal hN3-H10S to human NTPDase3 (42), guinea pig rN8-8C to rat NTPDase8 (15), rabbit rNU-9L (30) and guinea pig rNU-4C to rat ecto-5=-nucleotidase/CD73 (16), a commercially available mouse monoclonal antibody to human ecto-5=-nucleotidase (clone 4G4; HyCult Biotechnology, Uden, The Netherlands) and polyclonal antibodies specific for pancreatic hormones, both guinea pig anti-insulin and anti-pancreatic polypeptide (Millipore, St. Charles, MO), rabbit anti-glucagon (BioGenex, San Ramon, CA), and goat anti-somatostatin (Santa Cruz Biotechnology, Santa Cruz, CA). Secondary antibodies used were biotinylated goat anti-guinea pig and goat anti-rabbit (Jackson ImmunoResearch Laboratories, West Grove, PA) as well as goat anti-mouse (Vector Laboratories, Burlington, ON, Canada); Alexa fluor 594 donkey anti-rabbit, Alexa fluor 594 goat anti-guinea pig, Alexa fluor 633 goat anti-mouse, Alexa fluor 488 goat anti-rabbit, and Alexa fluor 488 rabbit anti-goat (Invitrogen); FITC-conjugated goat anti-guinea pig (Jackson ImmunoResearch Laboratories) and goat anti-rabbit (Santa Cruz Biotechnology); and finally, an unconjugated goat antiguinea pig (Vector Laboratories).
Enzyme Histochemistry, Immunohistochemistry, and Immunofluorescence
Tissue processing. C57BL/6 mice were obtained from Taconic (Huston, NY). All procedures were approved by the Canadian Council on Animal Care and the Laval University Animal Welfare Committee.
Human pancreas samples obtained from organ donors histologically checked by random sections and confirmed to be free of disease were kindly provided by the Department of General Surgery of the Technische Universität München (Munich, Germany; ethics approval no. 1926/07).
For enzyme histochemistry (EHC) and immunohistochemistry (IHC), freshly excised pancreatic tissues were embedded in TissueTek OCT freezing medium (Sakura Fintek, Torrance, CA), snapfrozen in isopentane cooled in a bain-marie with dry ice/EtOH, and stored at Ϫ80°C until they were used. Sections of 6 m were prepared and fixed in 10% phosphate-buffered formalin mixed with cold acetone (Fisher Scientific, Ottawa, ON, Canada) before further processing. For double-staining immunofluorescence experiments, the excised mouse pancreas tissue samples were successively fixed with 4% paraformaldehyde, immersed in a sucrose solution followed by inclusion in OCT freezing medium, and then sectioned and processed for staining. Sections were counterstained with aqueous hematoxylin or DAPI, mounted in Mowiol mounting medium, and examined under a BX51 Olympus microscope or a FV300 Olympus confocal microscope.
Enzyme histochemistry. Ectonucleotidase activities in pancreas sections were visualized using the Wachstein/Meisel lead phosphate precipitation method, performed as described (40) . Briefly, fixed tissue sections were preincubated for 30 min at 25°C in Tris-maleate buffer (2 mM CaCl 2, 250 mM sucrose, 50 mM Tris-maleate, pH 7.4) supplemented with 2.5 mM levamisole as an inhibitor of alkaline phosphatases. Enzymatic reaction for the hydrolysis of 200 M nucleotides was performed for 2 h at 37°C in the same buffer supplemented with 5 mM MnCl2, 2 mM Pb(NO3)2, and 3% dextran T-250 (wt/vol). For control experiments, the substrate was omitted. The reaction was revealed by the incubation of tissue sections with 1% (NH4)2S (vol/vol) for 1 min. For ecto-5=-nucleotidase inhibition experiments, 1 mM ␣,␤-meADP was added to both preincubation and enzymatic reaction buffers.
IHC. IHC (peroxidase-based activity) experiments were performed as described previously (40) . Briefly, tissue sections were incubated for 18 h at 4°C with the indicated primary antibodies and then for 1 h at 25°C with the appropriate biotinylated secondary antibodies. Preimmune sera or appropriate purified isotype control immunoglobulins, when available, were routinely included as controls.
Double-staining immunofluorescence. Double-staining experiments were performed as described previously (40) . The tissue sections were processed for the staining of the first antigen as follows: the first primary antibody was incubated for 18 h at 4°C, and then the first secondary antibody was applied for 1 h at 25°C. The tissue sections were further stained for the second antigen under similar experimental conditions, except that the second primary antibody was incubated for 90 min at 25°C. . Inset: control experiment where substrate was omitted. NTPDase-like activity is detected with all substrates in Langerhans islets cells, in blood vessels, and in the luminal membrane of acinar cells. ATPase and UTPase activities are also present in conjunctive tissue areas surrounding islets and acini. Bottom [immunohistochemistry (IHC)]: immunostaining of NTPDase1, -2, and -3. NTPDase1 expression localizes in blood vessels, capillaries, and acinar cells. NTPDase2 is seen in conjunctive tissues surrounding blood vessels, capillaries, acini, and Langerhans islets. NTPDase3 is immunodetected in Langerhans islet cells. NTPDase3-Pi corresponds to staining control using guinea pig preimmune serum that is devoid of reaction. Nuclei were counterstained with aqueous hematoxylin. Scale bar, 25 m. B: AMPase activity and ecto-5=-nucleotidase immunolocalization in mouse, rat, and human pancreas serial sections. Top [EHC (AMP)]: ectoAMPase activity using 200 M AMP as substrate. In both mouse and human pancreas, the AMPase activity is associated mainly with the vascular components. Langerhans islet cells are devoid of any hydrolytic activity. In humans, AMPase activity is also associated with conjunctive tissue areas. In the rat, Langerhans islet cells, vascular elements, and luminal areas of acini show a prominent AMPase activity that is fully inhibited in the presence of 1 mM adenosine 5=-(␣,␤-methylene) diphosphate (␣,␤-meADP), a specific ecto-5=-nucleotidase (ecto-5=-NT) inhibitor (rat EHC; top right, inset). Bottom [IHC (ecto-5=-NT)]: ecto-5=-nucleotidase immunostaining correlated with the distribution pattern of AMPase activity for all species. Insets correspond to antibody control staining, mouse IgG1 isotype (human), or preimmune serum (both mouse and rat). *Langerhans islets. Nuclei were counterstained with aqueous hematoxylin. Scale bar, 25 m. C: a double immunofluorescence staining experiment performed on a rat pancreatic section shows that NTPDase3-positive (red) cells also express ecto-5=-NT (green). Nuclei were counterstained with 4=,6-diamidino-2-phenylindole (DAPI; blue). Scale bar, 10 m.
When two primary antibodies raised in the same host were used, double-staining experiments were performed with the tyramide signal amplification (TSA) reagent-based technique, as described previously (3) . Briefly, the concentration of the first primary antibody was set below the detection limit with the fluorescently labeled secondary antibody. A biotin-conjugated secondary antibody was used to detect this highly diluted antibody prior to amplification with avidin-biotinperoxidase-linked complex (Vectastain Elite ABC kit; Vector Laboratories). The Alexa fluor 488-TSA reagent (Invitrogen) was used as substrate for the peroxidase enzyme that catalyzes its hydrolysis to produce a fluorescent precipitate. An additional incubation step with an unconjugated secondary antibody was performed to block residual free highly diluted primary antibodies. The second primary antibody was then applied at a standard working concentration and detected with a conventional Alexa fluor-conjugated secondary antibody.
Cell Transfection, Protein Preparation, and Ectonucleotidase Activity Assays
Activity assays were performed using either protein extracts of transfected COS-7 and human embryonic kidney (HEK)-293 cells or intact rat INS-1 (832/13) pancreatic ␤-cells kindly provided by Dr. C. B. Newgard, Duke University Medical Center (Durham, NC), and grown as described (24) . For the activity assays with protein extracts, transfection of COS-7 and HEK-293 cells with a pcDNA3.1 plasmid encoding rat NTPDase3 (59) and protein preparation was performed as described previously (32) . Protein concentration was estimated with the Bradford microplate assay, using BSA as a standard (6) . NTPDase3 activity assays were performed as described previously (41) in a Tris-calcium buffer (5 mM CaCl 2 and 80 mM Tris·HCl, pH 7.4), using ATP or ADP (100 M) as substrates, with or without the indicated concentration of inhibitors.
The ectonucleotidase activity on intact cells was assayed as described previously (31, 32) . Briefly, the activity of confluent INS-1 (832/13) monolayers was measured in 24-well plates in Tris-calcium buffer supplemented with 145 mM NaCl when either ATP or ADP (100 M) was used as substrate or in Tris-magnesium buffer (5 mM MgCl2, 145 mM NaCl, and 80 mM Tris·HCl, pH 7.4) when AMP (100 M) was used as substrate. The inhibitory effects of NF279 (100 M) or BG0136 (5 mM) on the ATPase and ADPase activities of confluent INS-1 (832/13) monolayers in 48-well plates were determined in a Krebs-HEPES buffer [in mM: 114 NaCl, 4.7 KCl, 1.2 KH2PO4, 1.16 MgSO4, 20 HEPES, 2.5 CaCl2, 25.5 NaHCO3, 3 D-glucose, pH 7.2, with 0.1% fatty acid-free BSA (wt/vol)] with either ATP or ADP (100 M) as substrate.
The measurement of ectonucleotidase activity was performed by measuring either the Pi released by the malachite green technique (4) or the nucleotide contents of intact cell supernatants obtained in phosphate-based Krebs-HEPES buffers, using HPLC. For HPLC experiments, adenine nucleotides were transformed into their fluorescent etheno(ε)-derivatives, according to a modified derivatization protocol by Lazarowski et al. (33) and Levitt et al. (37) . This transformation increased the sensitivity of nucleotide detection ϳ50-fold and allowed the dilution of the samples that was necessary to decrease the amount of NTPDase3 inhibitors loaded on the HPLC column that could otherwise be permanently retained by the nucleotide separation matrix and cause its failure or reduce its half-life. In a representative derivatization assay, 200-l aliquots of the 400-folddiluted supernatants were incubated for 1 h at 70°C in the presence of 1 mM ClCH2CHO and 25 mM Na2HPO4 (pH 4.0) in a final volume of 250 l. The resulting fluorescent ethenoadenylated derivatives (ε-ATP, ε-ADP, ε-AMP, and ε-adenosine) were separated by reverse-phase HPLC, as described previously (31), except for the mobile phase, which contained 25 mM tetrabutylammonium hydrogen sulphate and 100 mM KH2PO4-K2HPO4, pH 7.0, with 20% methanol (vol/vol). Identification and quantification of ethenoadenylated derivatives were performed with an automated Waters and Beckman HPLC apparatus equipped with a Shimadzu RF-10Axl fluorescence detector (Shimadzu Scientific Instruments, Columbia, MD).
Glucose-Stimulated Insulin Secretion
Glucose-stimulated insulin secretion (GSIS) experiments were performed using rat INS-1 (832/13) pancreatic ␤-cells that express human insulin under the control of a cytomegalovirus promoter, according to Hohmeier et al. (24) . Forty-eight hours before the secretion experiments, cells were seeded in 48-well plates (250,000/ well) in a cell growth medium containing 11 mM glucose. Cells were washed and preincubated in Krebs-HEPES buffer containing 3 mM D-glucose (basal glucose condition) for 2 h at 37°C. The solution was then replaced with fresh buffer containing D-glucose at the indicated concentration for 2 h at 37°C. The resulting supernatants were collected, and insulin was measured using a human insulin ELISA assay kit (ALPCO Diagnostics, Salem, NH). In some experiments, the NTPDase3 inhibitors NF279 (100 M) (41) and BG0136 (5 mM) (12, 18) were added to both preincubation and incubation buffers.
Flow Cytometry
INS-1 (832/13) cells were collected from culture plates using Accutase Enzyme Cell Detachment Medium, following the manufacturer's instructions (eBioscience, San Diego, CA). Next, these cells were incubated with specific anti-rat NTPDase and ecto-5=-nucleotidase polyclonal antibodies in PBS buffer with 1% FBS (vol/vol) and 0.1% NaN 3 (wt/vol), washed, and then incubated with FITC-conjugated secondary antibodies. Preimmune sera were used as negative controls. Cell analysis was then performed using a Coulter EPICS XL flow cytometer (Beckman Coulter Canada, Mississauga, ON, Canada).
Statistical Analysis
Analysis of insulin secretion data was done with paired Student's t-tests using the Graphpad Prism 5.0 software (GraphPad Software, La Jolla, CA).
RESULTS
Murine Langerhans Islet Cells Express NTPDase3
EHC experiments showed that, within mouse pancreatic tissues, Langerhans islets as well as blood vessels, conjunctive tissue, and acinar cells display a broad nucleotidase activity, with both adenylic and uracylic tri-and diphosphonucleoside hydrolysis. Enzyme histochemical assays were performed in the presence of the alkaline phosphatase inhibitor levamisole. The latter observation suggests that an NTPDase-like ectoenzyme is responsible for this activity (EHC; Fig. 1A ). The expression of NTPDase1, -2, and -3 in mouse pancreas was revealed by IHC on tissue sections (Fig. 1A) . NTPDase1 and NTPDase2 protein expression was observed in blood vessels as well as in capillaries inside the islets (IHC; Fig. 1A ). NTPDase1 was also detected in acinar cells, and NTPDase2 was detected in the connective tissue areas surrounding the islets and acini, as described previously (29) . NTPDase3 expression was observed exclusively in Langerhans islet cells. NTPDase8 was not detected (data not shown). Similar NTPDase activity and protein expression patterns were observed in rat (Supplemental Fig. S1 ; Supplemental Material for this article can be found online at the AJP-Endocrinology and Metabolism web site) and human (42) pancreas sections. It is noteworthy that the combined expression pattern of NTPDase1, -2, and -3 corresponded to the distribution of hydrolytic activities toward ATP, UTP, ADP, and UDP in the pancreas in all of the abovementioned species (Fig. 1A and Supplemental Fig. S1 ).
We also investigated the activity and expression of ecto-5=-nucleotidase in Langerhans islets, where a notable disparity between species was observed. Indeed, rat Langerhans islet cells displayed AMPase activity that was not detected either in human or in mouse species [EHC (AMP); Fig. 1B] . The immunohistochemical localization of ecto-5=-nucleotidase [IHC (ecto-5=-NT); Fig. 1B] and the nearly complete inhibition of AMPase activity by ␣␤-MeADP, an inhibitor of this enzyme (61) , suggest that ecto-5=-nucleotidase is the enzyme responsible for most, if not all, AMP hydrolysis in rat Langerhans islets. Double-staining immunofluorescence experiments confirmed that ecto-5=-nucleotidase coexpressed with NTPDase3 in rat Langerhans islets (Fig. 1C) . Although absent from mouse and human Langerhans islet cells, ecto-5=-nucleotidase was expressed by capillaries located within the islets in all species analyzed. Therefore, the immunolocalization of ecto-5=-nucleotidase mirrored the AMPase activity in all regions in the three species analyzed.
Taken together, these data demonstrate that the pancreatic endocrine cells of human, rat, and mouse Langerhans islets specifically express NTPDase3, whereas ecto-5=-nucleotidase is expressed in these cells in rat but not in mouse or human.
NTPDase3 is Expressed by All Types of Langerhans Islet Cells
Langerhans islets are formed by four endocrine cell subsets named ␣-cells, ␤-cells, ␦-cells, and PP cells, which secrete glucagon, insulin, somatostatin, and pancreatic polypeptide, respectively (13) . Antibodies to these hormones were used as specific cell markers in double immunofluorescence staining experiments to determine which cell type(s) expresses NTPDase3 in Langerhans islets. As shown in Fig. 2A , all hormone-producing cells in mouse islets expressed NTPDase3. As expected, the double immunofluorescence staining patterns did not match perfectly due to the different subcellular localizations of these polypeptides, i.e., the hormones being stored in intracellular granules and NTPDase3 being localized in the plasma membrane. Except for human PP cells that were not tested, similar data were obtained with rat and human pancreatic sections, as shown for insulin-producing ␤-cells in Fig. 2B (for the other cell types, see Supplemental. Fig. S2 ). These results demonstrate that NTPDase3 is expressed by all Langerhans islet cells, including insulin-producing ␤-cells.
NTPDase3 Modulates Insulin Secretion by Rat ␤-Cells
The expression of NTPDase3 in ␤-cells suggests that this enzyme might regulate P2 receptor-dependent insulin secretion. This hypothesis was tested using the rat cell line INS-1 (832/13), which represents a well-established model for the study of insulin secretion (24) .
Flow cytometry experiments performed with specific polyclonal antibodies against rat membrane-bound NTPDases and ecto-5=-nucleotidase confirmed the expression of NTPDase3 and ecto-5=-nucleotidase (Fig. 3A) and the lack of expression of NTPDase1, -2, and -8 in these cells (data not shown). In keeping with these data, intact INS-1 (832/13) cells hydrolyzed ATP and ADP as well as AMP (Fig. 3B) . This cell line was thus used to test the potential contribution of NTPDase3 activity to insulin secretion.
To address this hypothesis, INS-1 (832/13) cells were stimulated with glucose in the presence or absence of NTPDase3 inhibitors. The cells were incubated with glucose at the following concentrations, namely 1) 3 mM, which reflects the conditions for basal insulin release, 2) 6 mM, which corresponds to an intermediate glucose concentration, and 3) 8.3 and 15 mM, which yield a maximal insulin secretion, as described previously in that cell line (24) . To inhibit NTPDase3 activity, we used BG0136 that was described previously as a potent inhibitor of NTPDase activity (mainly NTPDase1) in a bovine spleen particulate fraction (18) and NF279 that was described originally as a P2X 1 antagonist and has recently been reported to potently inhibit NTPDase1 and -3 from mouse and human (41) . We tested the potency of these inhibitors on ATP and ADP hydrolysis by recombinant rat NTPDase3 protein extracts. As shown in Fig. 4A , both BG0136 and NF279 fully inhibited ATP and ADP hydrolysis by recombinant NTPDase3. The IC 50 values for the inhibition of ATP and ADP (100 M) hydrolysis were 44 and 30 M, respectively, for BG0136 and 0.67 and 0.63 M, respectively, for NF279. We had observed previously that the efficacy of NTPDase inhibitors against both ATPase and ADPase activi- ties was often lower in intact cells compared with protein extracts (36) . Therefore, BG0136 and NF279 were used at concentrations sufficient to completely inhibit recombinant rat NTPDase3 activity, i.e., at 5 mM and 100 M, respectively. In intact INS-1 (832/13) cells, both compounds strongly decreased ATPase and ADPase activities (Ͼ60%; Fig. 4B ) in Krebs-HEPES buffer, whereas ecto-5=-nucleotidase activity was virtually unaffected (data not shown). In agreement with our hypothesis, INS-1 (832/13) cells secreted significantly more insulin in the presence of either BG0136 or NF279, but only when incubated with 3 mM glucose, since no insulin secretion increase was observed when the cells were stimulated with moderate (6 mM) or high (8.3 or 15 mM) glucose concentrations (Fig. 5A) . Further assays, under hypoglycemic conditions (i.e., 3 mM), were also performed without glucose addition or in the presence of 1 mM glucose, and NTPDase3 inhibition under these conditions significantly increased insulin secretion, as observed with 3 mM glucose (data not shown).
We next investigated the effect of exogenous ATP (100 M) on the response of INS-1 (832/13) cells to glucose. At a low glucose concentration (3 mM), exogenous ATP had no effect on insulin secretion, and the NTPDase3 inhibitors still increased insulin secretion in the presence of ATP. In contrast, at the high glucose concentrations (8.3 or 15 mM), 100 M ATP significantly decreased insulin secretion, and this reduction was abolished by BG0136 and NF279 [15 mM; Fig. 5B (data not shown for 8.3 mM glucose)]. This suggests that, at high glucose and ATP concentrations, an ATP degradation product, most likely adenosine [via adenosine receptor(s)], was responsible for the observed reduction in insulin release by INS-1 (832/13) cells, whereas under hypoglycemic conditions, certain P2 receptors that are more strongly activated in the presence of NTPDase3 inhibitors might be involved.
DISCUSSION
This work shows that hormone-secreting cells in human, rat, and mouse Langerhans islets express the NTPDase3 ectonucleotidase. The presence of NTPDase3 in all types of islet cells was confirmed by double immunofluorescence staining with specific markers of ␣-, ␤-, and ␦-cells and PP cells. The existence of an ectonucleotidase in the endocrine pancreas had been suggested by previous studies reporting that both intact and homogenates of murine Langerhans islets hydrolyze ATP and ADP (22, 54, 55) , an activity that was sensitive to sodium azide and dependent on the presence of Mg 2ϩ (54) . These observations are all in agreement with the presence of NTPDase3. We also show here that both NTPDase1 and NTPDase2 are expressed in the capillaries of Langerhans islets and that NTPDase2 is also expressed in conjunctive tissue around the islets.
In addition, we herein demonstrate that NTPDase3 modulates the secretion of insulin by the rat ␤-cell line INS-1 (832/13). These data are in line with several reports indicating that extracellular nucleotides play a role in insulin secretion (for review, see Ref. 48) . More specifically, the GSIS assays (Fig. 5A) suggest that NTPDase3 activity regulates the basal insulin secretion present at low glucose concentrations but not that induced by moderate or high glucose levels unless another source of ATP is implemented to the cells, for instance, such as that expected in vivo under some inflammatory conditions and/or disease states. It was previously shown that the activation of P2X receptors induces a moderate increase of insulin release at low glycemia (17, 47) . Both rat INS-1 (832/13) cells and rat primary pancreatic ␤-cells express P2X 2 , P2X 3 , P2X 4 , and P2X 6 receptors (49). Thus, the effect of NTPDase3 on basal insulin secretion might be mediated via the regulation of one or several P2X receptors in rat INS-1 (832/13) cells. Similar results can be expected for human ␤-cells in which extracellular nucleotides also increase insulin secretion (17) . Indeed, after this article was submitted, a study was published showing that ARL 67156, an inhibitor of ectonucleotidases, significantly increased insulin secretion from human pancreatic islets at low glucose concentrations (26) . It is noteworthy that we have reported recently that ARL 67156 was an inhibitor of human NTPDase1, NTPDase3, and NPP1 (36) . In mouse, it is difficult to speculate on the function of NTPDase3 activity in insulin secretion by ␤-cells, since it has been reported that in this species extracellular nucleotides can either diminish (34, 44, 46) , or stimulate this response (2, 45) .
Interestingly, the present results suggest that the role of NTPDase3 in insulin secretion by rat ␤-cells may depend on the glucose concentration and on the level of extracellular ATP. Indeed, at 15 mM glucose, the addition of exogenous ATP (100 M) resulted in a decrease in insulin secretion, and this effect was abolished by NTPDase3 inhibitors (Fig. 5B) . These results suggest that, under the above conditions, the role of NTPDase3 in insulin secretion would involve adenosine production, which was reported to inhibit rat insulin secretion (8, 23) . In agreement with this view, the study by Verspohl et al. (58) showed a biphasic effect of exogenous ATP on insulin secretion by rat ␤-cells. Specifically, low concentrations of ATP activated this response, whereas high ATP concentrations inhibited it. The latter effect of ATP was proposed to involve its hydrolysis to adenosine and the subsequent activation of A 1 receptors (58). Although we cannot rule out that the increased secretion of insulin induced by NTPDase inhibitors with 3 mM glucose (Fig. 5A ) could also be due to decreased production of adenosine, it has been shown that exogenous adenosine does not modulate rat insulin secretion at basal glucose levels (8) . Therefore, these results suggest that, in rat ␤-cells at low glycemia, NTPDase3 activity controls insulin secretion via the modulation of P2 receptor activation. In addition, it might be speculated that since exogenous ATP had no effect on basal insulin secretion, the endogenous ATP release would be sufficient for this response (3 mM; Fig. 5B ). Alternatively, NTPDase3 could be localized in the plasma membrane in the close vicinity of the P2 receptor(s) that control(s) insulin secretion, blocking any effects from exogenous ATP by preempting the activation of the P2 receptors by this ligand (35) .
In keeping with the role of NTPDase3 in adenosine production, we show here that both rat Langerhans islet and INS-1 (832/13) cells express ecto-5=-nucleotidase (Figs. 1, B and C,  and 3) , the rate-limiting enzyme at physiological pH for the production of adenosine. This observation is in agreement with a previous report suggesting the existence of an AMP-degrading enzyme in rat Langerhans islets (22) . The combined activities of NTPDase3 and ecto-5=-nucleotidase in rat ␤-cells drive the sequential hydrolysis of ATP to adenosine, which in turn inhibits insulin secretion through A 1 receptor activation. This hypothesis is supported by the fact that the inhibition of NTPDase3 by BG0136 and NF279 reversed the effect of exogenous ATP on insulin secretion, which was likely due to the inhibition of AMP production by NTPDase3. Surprisingly, we found that ecto-5=-nucleotidase expression is peculiar to rat since human and mouse islet cells did not exhibit any staining for this enzyme or for AMPase activity. Although adenosine has been shown to modulate insulin secretion in mouse ␤-cells (5, 27) , the latter do not express ecto-5=-nucleotidase. These data suggest that A 1 receptor activation by adenosine in mouse ␤-cells would be modulated differently than in rat ␤-cells. For example, in the published study by Johansson et al. (27) , experiments were performed on perfused pancreas, and therefore, an adenosine source might have been provided by another pancreatic cell type and might have activated A 1 receptor on ␤-cells via a paracrine effect. Further investigation is needed to clarify the source of adenosine in mouse. Unlike in murine ␤-cells, adenosine does not appear to regulate insulin secretion in human cells (26) . This is correlated with the absence of ecto-5=-nucleotidase in human ␤-cells as observed here.
We cannot exclude that, in addition to NTPDase3 inhibition, BG0136 and NF279 might antagonize some P2 receptors. At the concentrations used in this study, BG0136 may affect P2Y 2 (18) , whereas NF279 may antagonize P2X 1 , P2X 2 , and/or P2X 7 (7) . However, the fact that these two structurally unrelated NTPDase3 inhibitors modulated insulin secretion to a similar extent suggests that their effects are due solely to NTPDase3 inhibition.
Interestingly, signaling pathways activated by extracellular nucleotides are also implicated in the secretion of glucagon and somatostatin by ␣-and ␦-cells, respectively (19, 52, 56) . Since NTPDase3 is also expressed by these cell types, this ectonucleotidase might regulate their secretion. This will be the object of future studies.
In summary, this study has identified the ectonucleotidases expressed in Langerhans islets. More specifically, NTPDase3 was expressed by all four pancreatic endocrine cells (␣, ␤, ␦, and PP) in rat, mouse, and human. Interestingly, ecto-5=-nucleotidase was coexpressed in these cells, with NTPDase3 only in the rat, and in neither mouse nor human. Importantly, the inhibition of NTPDase3 activity increased insulin secretion by rat ␤-cells under hypoglycemia, probably by regulating P2 receptor activation. In addition, NTPDase3, probably by working in tandem with the ecto-5=-nucleotidase, also participated to the regulation of insulin secretion at high glucose and ATP concentrations, most likely by controlling adenosine production. Thus, if these effects are confirmed in humans, NTPDase3 could be considered as a potential target for the regulation of insulin secretion.
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